Tools   Select Another Resource Report Type

https://www.uab.edu/medicine/obriencenter/cores/bioanalytical-core

Core that provides bioenergetics, oxidative stress analysis and metabolite analysis support for AKI research. It includes protocols and technology for bioanalytical analysis of oxidative stress and cellular bioenergetics as well as post-translational modifications.

Proper citation: UAB-UCSD Core Center for Acute Kidney Injury Research Bioanalytical Core (RRID:SCR_015280) Copy   

•   Source: SciCrunch Registry

https://www.uab.edu/medicine/obriencenter/cores/pre-clinical-studies-of-aki

Core that provides services such as expertise in development and training in the use of rodent models of AKI, specifically in the setting of ischemia/reperfusion (I/R) injury, sepsis and renal transplantation, gamma-ray imaging (gamma camera, microSPECT/CT, microPET/CT), metabolic assessments of kidney O2 consumption, and technical expertise in isolation of primary renal and vascular cell in culture.

Proper citation: UAB-UCSD Core Center for Acute Kidney Injury Research Pre-Clinical Studies of AKI (RRID:SCR_015278) Copy   

•   Source: SciCrunch Registry

https://www.uab.edu/medicine/obriencenter/center-overview/administration

Core facility which coordinates the various activities of the center. Its various duties include facilitating interactions and collaboration among the researchers of the center, promoting scientific development through education and Pilot funding, organizing and supporting seminars, journal clubs and symposia, and maintaining communication with members.

Proper citation: UAB-UCSD Core Center for Acute Kidney Injury Research Administrative Core (RRID:SCR_015279) Copy   

•   Source: SciCrunch Registry

http://www.mayo.edu/research/centers-programs/model-systems-core/overview

Core that makes available PKD model systems and technologies to PKD researchers at Mayo and at other institutions. Its services include C. elegans PKD-targeted services, Zebrafish PKD-targeted services, and Rodent PKD-targeted services.

Proper citation: Translational Polycystic Kidney Disease (PKD) Center at Mayo Clinic Rochester Model Systems Core (RRID:SCR_015312) Copy   

•   Source: SciCrunch Registry

http://archives.niddk.nih.gov/patient/aask/aask.aspx

Clinical trial investigating whether a specific class of antihypertensive drugs (beta-adrenergic blockers, calcium channel blockers, or angiotensin converting enzyme inhibitors) and/or the level of blood pressure would influence progression of hypertensive kidney disease in African Americans. The initiative consisting of 21 clinical centers and a data-coordinating center is followed by a Continuation of AASK Cohort Study to investigate the environmental, socio-economic, genetic, physiologic, and other co-morbid factors that influence progression of kidney disease in a well-characterized cohort of African Americans with hypertensive kidney disease. Only patients who were previously in the randomized trial are eligible for the cohort study. A significant discovery was made in the treatment strategy for slowing kidney disease caused by hypertension. Angiotensin-converting enzyme (ACE) inhibitors, compared with calcium channel blockers, were found to slow kidney disease progression by 36 percent, and they drastically reduced the risk of kidney failure by 48 percent in patients who had at least one gram of protein in the urine, a sign of kidney failure. ACE inhibitors have been the preferred treatment for hypertension caused by diabetes since 1994; however, calcium channel blockers have been particularly effective in controlling blood pressure in African Americans. The AASK study now recommends ACE inhibitors to protect the kidneys from the damaging effects of hypertension. The Continuation of AASK Cohort Study will be followed at the clinical centers. The patients will be provided with the usual clinical care given to all such patients at the respective centers. Baseline demographic information, selected laboratory tests, and other studies are being obtained at the initiation of the Continuation Study. The patients will be seen quarterly at the centers, and some selected studies done at these visits. Samples will be obtained and stored for additional studies and analyses at a later date.

Proper citation: AASK Clinical Trial and Cohort Study (RRID:SCR_006985) Copy   

•   Source: SciCrunch Registry

https://www.cincinnatichildrens.org/research/divisions/n/nephrology/center-of-excellence

Center whose goal is to support basic, translational, and clinical research on critical pediatric kidney diseases by focusing on Acute Kidney Injury, Nephrotic Syndrome, and Lupus Nephritis.

Proper citation: Pediatric Centers of Excellence in Nephrology at Cincinnati Children's Hospital Medical Center (RRID:SCR_015302) Copy   

•   Source: SciCrunch Registry

https://www.medibeacon.com/science/preclinical/

Transdermal Glomerular Filtration Rate monitor used to assess renal function in mouse and rat models of acute kidney injury and chronic kidney disease.

Proper citation: MediBeacon: Transdermal GFR Monitor (RRID:SCR_024533) Copy   

•   Source: SciCrunch Registry

http://www.perl-study.org

PERL is a clinical trial for people with type 1 diabetes who have early signs of kidney problems. Its goal is to test a new way to reduce loss of kidney function using a safe and inexpensive medicine.

Proper citation: Preventing Early Renal Loss in Diabetes (PERL) (RRID:SCR_015862) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00271999

Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia

Proper citation: Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) Copy   

•   Source: SciCrunch Registry

https://clinicaltrials.gov/study/NCT01885559

Consortium established to design and implement clinical trials of treatments that might slow the progressive loss of renal function in Polycystic Kidney Disease (PKD). Two multicenter randomized, double-blind, placebo controlled clinical trials are running concurrently to study the efficacy of renin-angiotensin-aldosterone system blockade on the progression of cystic disease (kidney volume) and on the decline in renal function in autosomal dominant polycystic kidney disease (ADPKD). Study A is to study whether intensive ACE-I/ARB blockade decrease the progression of cystic disease compared to ACE-I monotherapy patients with early disease, relatively preserved renal function, and high-normal BP or hypertension. Study B is to study whether intensive ACE-I/ARB blockade as compared to ACE-I monotherapy slow the decline in kidney function, end-stage of renal disease, or death in the setting of standard blood pressure control in hypertensive patients with moderately advanced disease.

Proper citation: HALT PKD (RRID:SCR_001529) Copy   

•   Source: SciCrunch Registry

http://medicine.iupui.edu/neph/obrien/probe

Core facility which develops and characterizes methods for expressing fluorescent biosensors in the rodent kidney to be paried with intravital microscopy.

Proper citation: Indiana O'Brien Center for Advanced Microscopic Analysis Probe Delivery Core (RRID:SCR_015274) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/medicine/hrfdcc/

Center that focuses on understanding the causes of Cystic Kidney Disease and other related disorder and the development of new therapeutic strategies.

Proper citation: UAB Hepatorenal Fibrocystic Diseases Core Center (RRID:SCR_015311) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/44

Randomized controlled clinical trial to understand how increasing hemodialysis to six times a week from the standard of three times a week may result in improved heart health. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialyis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale. In addition, main secondary outcomes have been designated for each of seven outcome domains: 1) cardiovascular structure and function (change in LV mass), 2) health-related quality of life/physical function (change in the PHC), 3) depression/burden of illness (change in Beck Depression Inventory), 4) nutrition (change in serum albumin), 5) cognitive function (change in the Trail Making Test B), 6) mineral metabolism (change in average predialysis serum phosphorus), and 7) clinical events (rate of non-access hospitalization or death). Hypertension and anemia are also main outcome domains, but without designation of single first priority outcomes.

Proper citation: Frequent Hemodialysis Network Daily Trial (RRID:SCR_001527) Copy   

•   Source: SciCrunch Registry

http://medicine.iupui.edu/neph/obrien/

Imaging center which provides renal and urological researchers access to intravital optical microscopy and 3-dimensional quantitative digital image analysis.

Proper citation: Indiana O'Brien Center for Advanced Microscopic Analysis (RRID:SCR_015271) Copy   

•   Source: SciCrunch Registry

https://usdrn.org/

Portal for research on urinary stones in adults and children in order to learn more about who forms kidney stones, treatments and prevention. Network comprises of experts including adult and pediatric urologists, adult and pediatric nephrologists, pediatricians, emergency department physicians, clinical trialists, nutritionists, behavioral scientists, and radiologists. Duke Clinical Research Institute is Scientific Data Research Center and with clinical sites including University of Pennsylvania Children Hospital of Philadelfia, University of Texas Southwestern Medical Center, University of Washington, Washington University in St. Louis, work together in planning, executing, and analyzing results from USDRN studies.

Proper citation: Urinary Stone Disease Research Network (RRID:SCR_019059) Copy   

•   Source: SciCrunch Registry

http://drc.ucsf.edu/

One of sixteen research centers established by the National Institute of Diabetes and Digestive and Kidney Diseases that fosters research and training in the areas of diabetes and related endocrine and metabolic disorders.

Proper citation: University of California San Francisco Diabetes Research Center (RRID:SCR_015102) Copy   

•   Source: SciCrunch Registry

http://dknet.org/

The NIDDK Information Network (dkNET) is a community-based network to serve needs of basic and clinical investigators that includes large pools of data and research resources relevant to mission of National Institute of Diabetes and Digestive and Kidney Disease.

Proper citation: NIDDK Information Network (dkNET) (RRID:SCR_001606) Copy   

•   Source: SciCrunch Registry

https://research.med.virginia.edu/pcen/

Center for the study of the development of the kidney during embryonic, fetal and postnatal life. As a collaboration between the University of Virginia and Tulane University, they use an interdisciplinary and inter-institutional approach for their research.

Proper citation: Pediatric Centers of Excellence in Nephrology at University of Virginia (RRID:SCR_015307) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/home/

NIDDK Central Repositories are two separate contract funded components that work together to store data and samples from significant, NIDDK funded studies. First component is Biorepository that gathers, stores, and distributes biological samples from studies. Biorepository works with investigators in new and ongoing studies as realtime storage facility for archival samples.Second component is Data Repository that gathers, stores and distributes incremental or finished datasets from NIDDK funded studies Data Repository helps active data coordinating centers prepare databases and incremental datasets for archiving and for carrying out restricted queries of stored databases. Data Repository serves as Data Coordinating Center and website manager for NIDDK Central Repositories website.

Proper citation: NIDDK Central Repository (RRID:SCR_006542) Copy   

•   Source: SciCrunch Registry

http://medicine.iupui.edu/neph/obrien/intravital

Core facility which primarily provides service, animal models, consultation training and intravital optical microscopy customized to kidney and urologic research. It also develops and characterizes novel biosensor probes and in vivo delivery methods for these probes, as well as intravital multiphoton microscopy technologies.

Proper citation: Indiana O'Brien Center for Advanced Microscopic Analysis Intravital Microscopy Core (RRID:SCR_015273) Copy   

•   Source: SciCrunch Registry